Qingdao Haier Biomedical Co.,Ltd

SHSE:688139 Stock Report

Market Cap: CN¥11.1b

Qingdao Haier BiomedicalLtd Future Growth

Future criteria checks 5/6

Qingdao Haier BiomedicalLtd is forecast to grow earnings and revenue by 30.1% and 24% per annum respectively. EPS is expected to grow by 30.1% per annum. Return on equity is forecast to be 13.5% in 3 years.

Key information

30.1%

Earnings growth rate

30.1%

EPS growth rate

Medical Equipment earnings growth25.4%
Revenue growth rate24.0%
Future return on equity13.5%
Analyst coverage

Low

Last updated10 Sep 2024

Recent future growth updates

Recent updates

Does Qingdao Haier BiomedicalLtd (SHSE:688139) Have A Healthy Balance Sheet?

Dec 11
Does Qingdao Haier BiomedicalLtd (SHSE:688139) Have A Healthy Balance Sheet?

Qingdao Haier BiomedicalLtd's (SHSE:688139) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 06
Qingdao Haier BiomedicalLtd's (SHSE:688139) Weak Earnings May Only Reveal A Part Of The Whole Picture

Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Stock Rockets 38% But Many Are Still Ignoring The Company

Oct 03
Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Stock Rockets 38% But Many Are Still Ignoring The Company

What Is Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Share Price Doing?

Sep 23
What Is Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Share Price Doing?

A Piece Of The Puzzle Missing From Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Share Price

Aug 19
A Piece Of The Puzzle Missing From Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Share Price

Is Qingdao Haier BiomedicalLtd (SHSE:688139) A Risky Investment?

Jun 14
Is Qingdao Haier BiomedicalLtd (SHSE:688139) A Risky Investment?

Is Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Potentially Undervalued?

May 21
Is Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Potentially Undervalued?

Further Upside For Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Shares Could Introduce Price Risks After 33% Bounce

Apr 26
Further Upside For Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Shares Could Introduce Price Risks After 33% Bounce

Further Upside For Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Shares Could Introduce Price Risks After 33% Bounce

Apr 26
Further Upside For Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Shares Could Introduce Price Risks After 33% Bounce

Earnings and Revenue Growth Forecasts

SHSE:688139 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,027813N/A9063
12/31/20253,346672N/A6843
12/31/20242,747542N/A6643
9/30/20242,23735854196N/A
6/30/20242,23436235195N/A
3/31/20242,28140633220N/A
12/31/20232,28140672249N/A
9/30/20232,615497385606N/A
6/30/20232,867579294562N/A
3/31/20232,987625358641N/A
12/31/20222,864601338632N/A
9/30/20222,68160882342N/A
6/30/20222,466573315559N/A
3/31/20222,276539334565N/A
12/31/20212,126845387592N/A
9/30/20211,941807556730N/A
6/30/20211,735799566681N/A
3/31/20211,549732708777N/A
12/31/20201,402381608697N/A
9/30/20201,266321427522N/A
6/30/20201,166254277409N/A
3/31/20201,078223116278N/A
12/31/20191,013182112280N/A
9/30/201995217327207N/A
12/31/201884211480149N/A
12/31/201762160N/A148N/A
12/31/2016482123N/A221N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688139's forecast earnings growth (30.1% per year) is above the savings rate (2.8%).

Earnings vs Market: 688139's earnings (30.1% per year) are forecast to grow faster than the CN market (25.2% per year).

High Growth Earnings: 688139's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688139's revenue (24% per year) is forecast to grow faster than the CN market (13.6% per year).

High Growth Revenue: 688139's revenue (24% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688139's Return on Equity is forecast to be low in 3 years time (13.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 01:09
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Qingdao Haier Biomedical Co.,Ltd is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Zhu ChenCitic Securities Co., Ltd.
Shuo SongCitic Securities Co., Ltd.